(Q43659682)

25 November 2017

0 references

Beyond the null hypothesis--do the HERS results disprove the estrogen/coronary heart disease hypothesis? (English)

1 reference

25 November 2017

3

Reis SE

2 references

ORCID Public Data File 2021

25 November 2017

4

Post WS

1 reference

25 November 2017

Blumenthal RS

1

1 reference

25 November 2017

Zacur HA

series ordinal

2

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

American Journal of Cardiology

25 November 2017

published in

1 reference

25 November 2017

volume

85

1 reference

25 November 2017

issue

8

1 reference

25 November 2017

page(s)

1015-1017

1 reference

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

The protective effects of estrogen on the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Design of the Women’s Health Initiative Clinical Trial and Observational Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Hormone replacement therapy, inflammation, and hemostasis in elderly women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900921-2

10.1016/S0002-9149(99)00921-2

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference